Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 140

1.

Clinical pharmacokinetics of thalidomide.

Teo SK, Colburn WA, Tracewell WG, Kook KA, Stirling DI, Jaworsky MS, Scheffler MA, Thomas SD, Laskin OL.

Clin Pharmacokinet. 2004;43(5):311-27. Review.

PMID:
15080764
2.

Biomarkers, validation and pharmacokinetic-pharmacodynamic modelling.

Colburn WA, Lee JW.

Clin Pharmacokinet. 2003;42(12):997-1022. Review.

PMID:
12959633
3.

Biomarkers in drug discovery and development: from target identification through drug marketing.

Colburn WA.

J Clin Pharmacol. 2003 Apr;43(4):329-41. Review.

PMID:
12723454
4.

Thalidomide dose proportionality assessment following single doses to healthy subjects.

Teo SK, Scheffler MR, Kook KA, Tracewell WG, Colburn WA, Stirling DI, Thomas SD.

J Clin Pharmacol. 2001 Jun;41(6):662-7.

PMID:
11402635
5.
6.

Pharmacokinetic/pharmacodynamic modeling in drug research and development.

Derendorf H, Lesko LJ, Chaikin P, Colburn WA, Lee P, Miller R, Powell R, Rhodes G, Stanski D, Venitz J.

J Clin Pharmacol. 2000 Dec;40(12 Pt 2):1399-418. Review.

PMID:
11185661
7.

Hemoglobin and methemoglobin concentrations after large-dose infusions of diaspirin cross-linked hemoglobin.

O'Hara JF Jr, Colburn WA, Tetzlaff JE, Novick AC, Angermeier KW, Schubert A.

Anesth Analg. 2001 Jan;92(1):44-8.

PMID:
11133598
8.

Effect of a high-fat meal on thalidomide pharmacokinetics and the relative bioavailability of oral formulations in healthy men and women.

Teo SK, Scheffler MR, Kook KA, Tracewell WG, Colburn WA, Stirling DI, Thomas SD.

Biopharm Drug Dispos. 2000 Jan;21(1):33-40.

PMID:
11038436
9.

An evolution of drug development and clinical pharmacology during the 20th century.

Heath G, Colburn WA.

J Clin Pharmacol. 2000 Sep;40(9):918-29.

PMID:
10975064
10.

Bioavailability and bioequivalence: average, population and/or individual.

Colburn WA, Keefe DL.

J Clin Pharmacol. 2000 Jun;40(6):559-60. No abstract available.

PMID:
10868304
11.

Single- and multiple-dose pharmacokinetics of ziprasidone in healthy young and elderly volunteers.

Wilner KD, Tensfeldt TG, Baris B, Smolarek TA, Turncliff RZ, Colburn WA, Hansen RA.

Br J Clin Pharmacol. 2000;49 Suppl 1:15S-20S.

12.

Single-dose oral pharmacokinetics of three formulations of thalidomide in healthy male volunteers.

Teo SK, Colburn WA, Thomas SD.

J Clin Pharmacol. 1999 Nov;39(11):1162-8.

PMID:
10579147
13.

Products approved for marketing during 1998.

Colburn WA.

J Clin Pharmacol. 1999 May;39(5):439-41. No abstract available.

PMID:
10234589
14.

Products approved for marketing during 1997.

Colburn WA.

J Clin Pharmacol. 1998 Mar;38(3):199-201. No abstract available.

PMID:
9549657
15.

Selecting and validating biologic markers for drug development.

Colburn WA.

J Clin Pharmacol. 1997 May;37(5):355-62. Review.

PMID:
9156368
16.

Toxicology evaluation and single intravenous dose studies in human subjects.

Colburn WA.

J Clin Pharmacol. 1997 Jan;37(1):4-6. No abstract available.

PMID:
9048266
17.

Phase I study of the safety and pharmacologic effects of diaspirin cross-linked hemoglobin solution.

Przybelski RJ, Daily EK, Kisicki JC, Mattia-Goldberg C, Bounds MJ, Colburn WA.

Crit Care Med. 1996 Dec;24(12):1993-2000.

PMID:
8968267
18.

Efficacy measures: surrogates or clinical outcomes?

Blue JW, Colburn WA.

J Clin Pharmacol. 1996 Sep;36(9):767-70. No abstract available.

PMID:
8889896
19.

Who is responsible for clinical pharmacology?

Colburn WA, Keefe DL.

J Clin Pharmacol. 1996 May;36(5):383-5. No abstract available.

PMID:
8739015
20.
21.

Pharmacologic profile of diaspirin cross-linked hemoglobin in hemodialysis patients.

Swan SK, Halstenson CE, Collins AJ, Colburn WA, Blue J, Przybelski RJ.

Am J Kidney Dis. 1995 Dec;26(6):918-23.

PMID:
7503066
22.

Another perspective on the cocktail strategy: "two glasses of wine or a six pack".

Colburn WA.

J Clin Pharmacol. 1995 Jul;35(7):655-7. No abstract available.

PMID:
7560244
23.

Surrogate biochemical markers: precise measurement for strategic drug and biologics development.

Lee JW, Hulse JD, Colburn WA.

J Clin Pharmacol. 1995 May;35(5):464-70. Review.

PMID:
7657845
24.

Surrogate markers and clinical pharmacology.

Colburn WA.

J Clin Pharmacol. 1995 May;35(5):441-2. No abstract available.

PMID:
7657842
25.

Drugs and endogenous ligands compete for receptor occupancy.

Colburn WA.

J Clin Pharmacol. 1994 Dec;34(12):1148-52. Review.

PMID:
7738208
26.

Clinical pharmacokinetics and relative bioavailability of oral procaterol.

Eldon MA, Battle MM, Coon MJ, Nordblom GD, Sedman AJ, Colburn WA.

Pharm Res. 1993 Apr;10(4):603-5.

PMID:
8483846
27.

Clinical pharmacokinetics of procaterol: dose proportionality after administration of single oral doses.

Eldon MA, Blake DS, Coon MJ, Nordblom GD, Sedman AJ, Colburn WA.

Biopharm Drug Dispos. 1992 Dec;13(9):663-9.

PMID:
1467453
28.

Influence of absorption rate, dosing frequency, and intrinsic pharmacokinetic profile on steady-state drug concentrations.

Eldon MA, Colburn WA.

Pharm Res. 1990 Jun;7(6):677-80. No abstract available.

PMID:
2367336
29.

Theophylline dosage adjustment during enoxacin coadministration.

Koup JR, Toothaker RD, Posvar E, Sedman AJ, Colburn WA.

Antimicrob Agents Chemother. 1990 May;34(5):803-7.

30.

Pharmacokinetic-pharmacodynamic relationships of methadone infusions in patients with cancer pain.

Inturrisi CE, Portenoy RK, Max MB, Colburn WA, Foley KM.

Clin Pharmacol Ther. 1990 May;47(5):565-77.

PMID:
2188771
31.

Multiple-dose propranolol administration does not influence the single dose pharmacokinetics of quinapril and its active metabolite (quinaprilat).

Horvath AM, Pilon D, Caillé G, Colburn WA, Ferry JJ, Frank GJ, Lacasse Y, Olson SC.

Biopharm Drug Dispos. 1990 Apr;11(3):191-6.

PMID:
2328305
32.

Controversy V: phase I, first time in man studies.

Colburn WA.

J Clin Pharmacol. 1990 Mar;30(3):210-22. No abstract available.

PMID:
2312779
33.

Differences in oral verapamil absorption as a function of time of day.

Eldon MA, Battle MM, Voigtman RE, Colburn WA.

J Clin Pharmacol. 1989 Nov;29(11):989-93.

PMID:
2600194
34.

The clinical pharmacokinetics of quinapril.

Olson SC, Horvath AM, Michniewicz BM, Sedman AJ, Colburn WA, Welling PG.

Angiology. 1989 Apr;40(4 Pt 2):351-9.

PMID:
2705643
35.
36.

Noncompartmental area under the curve determinations for drugs that cycle in the bile.

Colburn WA, Lucek RW.

Biopharm Drug Dispos. 1988 Sep-Oct;9(5):465-75.

PMID:
3224163
37.

Combined pharmacokinetic/pharmacodynamic (PK/PD) modeling.

Colburn WA.

J Clin Pharmacol. 1988 Sep;28(9):769-71. Review.

PMID:
3068258
38.

Pharmacokinetics of 14C-etretinate in healthy volunteers and two patients with biliary T-tube drainage.

Lucek RW, Dickerson J, Carter DE, Bugge CJ, Crews T, Vane FM, Cunningham W, Colburn WA.

Biopharm Drug Dispos. 1988 Sep-Oct;9(5):487-99.

PMID:
3066416
39.

Physiologic pharmacokinetic modeling.

Colburn WA.

J Clin Pharmacol. 1988 Aug;28(8):673-7. Review.

PMID:
3063730
40.

Relative and absolute bioavailability of prednisone and prednisolone after separate oral and intravenous doses.

Ferry JJ, Horvath AM, Bekersky I, Heath EC, Ryan CF, Colburn WA.

J Clin Pharmacol. 1988 Jan;28(1):81-7.

PMID:
3350994
41.

Effect of route of administration on the pharmacokinetics of etretinate in the dog.

Bornemann LD, Cotler S, Khoo KC, Carbone JJ, Colburn WA.

Biopharm Drug Dispos. 1988 Jan-Feb;9(1):119-26. No abstract available.

PMID:
2963666
42.

Determination of quinapril and its active metabolite in human plasma and urine by gas chromatography with electron-capture detection.

Ferry JJ, Horvath AM, Easton-Taylor M, Toothaker RD, Colburn WA.

J Chromatogr. 1987 Oct 9;421(1):187-91. No abstract available.

PMID:
3429565
43.

Pharmacokinetic/pharmacodynamic modeling: what it is!

Colburn WA.

J Pharmacokinet Biopharm. 1987 Oct;15(5):545-55.

PMID:
3694497
44.

Dose-proportional absorption of etretinate after doses of 25, 50, 75, and 100 mg.

Wills RJ, Rodriguez LC, Lin AH, Puccini C, Colburn WA.

Pharm Res. 1987 Oct;4(5):420-4.

PMID:
3508553
46.

Curve fitting and unique parameter identification.

Gibson DM, Taylor ME, Colburn WA.

J Pharm Sci. 1987 Aug;76(8):658-9. No abstract available.

PMID:
11002828
47.

Influence of food on the pharmacokinetics of quinapril and its active diacid metabolite, CI-928.

Ferry JJ, Horvath AM, Sedman AJ, Latts JR, Colburn WA.

J Clin Pharmacol. 1987 May-Jun;27(5):397-9.

PMID:
3693584
48.

Controversy. II: Bioequivalence as an indicator of therapeutic equivalence: modeling the theoretic influence of bioinequivalence on single-dose drug effect.

Olson SC, Eldon MA, Toothaker RD, Ferry JJ, Colburn WA.

J Clin Pharmacol. 1987 May-Jun;27(5):342-5. No abstract available.

PMID:
3693579
49.

Plasma concentration profiles of human recombinant interleukin-2 (HrIL-2) in the rat following administration by various systemic routes.

Colburn WA, Hakimi J, Bekersky I.

Drug Metab Dispos. 1987 May-Jun;15(3):429-31. No abstract available.

PMID:
2886323
50.

Pharmacokinetics and pharmacodynamics of methadone in patients with chronic pain.

Inturrisi CE, Colburn WA, Kaiko RF, Houde RW, Foley KM.

Clin Pharmacol Ther. 1987 Apr;41(4):392-401.

PMID:
3829576

Supplemental Content

Loading ...
Support Center